IN2013MU03309A - - Google Patents

Info

Publication number
IN2013MU03309A
IN2013MU03309A IN3309MU2013A IN2013MU03309A IN 2013MU03309 A IN2013MU03309 A IN 2013MU03309A IN 3309MU2013 A IN3309MU2013 A IN 3309MU2013A IN 2013MU03309 A IN2013MU03309 A IN 2013MU03309A
Authority
IN
India
Prior art keywords
pharmaceutically acceptable
acceptable derivative
cefepime
stereoisomer
compound
Prior art date
Application number
Inventor
Sachin Bhagwat
Mahesh Vithalbhai Patel
Original Assignee
Wockhardt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BR112016008979-0A priority Critical patent/BR112016008979B1/en
Priority to NZ719215A priority patent/NZ719215A/en
Priority to ES14806074T priority patent/ES2902456T3/en
Priority to CN202110966872.3A priority patent/CN113577084A/en
Priority to IN3309MU2013 priority patent/IN2013MU03309A/en
Priority to RU2016115376A priority patent/RU2702361C2/en
Priority to CN201480069915.6A priority patent/CN106102741A/en
Priority to CA2928364A priority patent/CA2928364C/en
Priority to DK14806074.2T priority patent/DK3060213T3/en
Priority to JP2016525054A priority patent/JP2016538258A/en
Application filed by Wockhardt Ltd filed Critical Wockhardt Ltd
Priority to US15/030,526 priority patent/US9827235B2/en
Priority to EP14806074.2A priority patent/EP3060213B1/en
Priority to AU2014338612A priority patent/AU2014338612C1/en
Priority to PCT/IB2014/065522 priority patent/WO2015059643A1/en
Priority to HUE14806074A priority patent/HUE057504T2/en
Priority to KR1020167013330A priority patent/KR102340010B1/en
Priority to MX2016005161A priority patent/MX2016005161A/en
Priority to PT148060742T priority patent/PT3060213T/en
Priority to PL14806074T priority patent/PL3060213T3/en
Publication of IN2013MU03309A publication Critical patent/IN2013MU03309A/en
Priority to JP2019083866A priority patent/JP6886996B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Pharmaceutical compositions comprising cefepime or a pharmaceutically acceptable derivative, and a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof are disclosed.
IN3309MU2013 2013-10-22 2014-10-22 IN2013MU03309A (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
US15/030,526 US9827235B2 (en) 2013-10-22 2014-10-22 Pharmaceutical compositions comprising antibacterial agents
NZ719215A NZ719215A (en) 2013-10-22 2014-10-22 Pharmaceutical compositions comprising antibacterial agents
CN202110966872.3A CN113577084A (en) 2013-10-22 2014-10-22 Pharmaceutical composition comprising an antibacterial agent
IN3309MU2013 IN2013MU03309A (en) 2013-10-22 2014-10-22
RU2016115376A RU2702361C2 (en) 2013-10-22 2014-10-22 Pharmaceutical compositions containing antibacterial agents
CN201480069915.6A CN106102741A (en) 2013-10-22 2014-10-22 Comprise the pharmaceutical composition of antiseptic
CA2928364A CA2928364C (en) 2013-10-22 2014-10-22 Pharmaceutical compositions comprising antibacterial agents
EP14806074.2A EP3060213B1 (en) 2013-10-22 2014-10-22 Pharmaceutical compositions comprising antibacterial agents
JP2016525054A JP2016538258A (en) 2013-10-22 2014-10-22 Pharmaceutical composition comprising an antibacterial agent
BR112016008979-0A BR112016008979B1 (en) 2013-10-22 2014-10-22 PHARMACEUTICAL COMPOSITIONS COMPRISING ANTIBACTERIAL AGENTS AND THEIR USES
ES14806074T ES2902456T3 (en) 2013-10-22 2014-10-22 Pharmaceutical compositions comprising antibacterial agents
DK14806074.2T DK3060213T3 (en) 2013-10-22 2014-10-22 Pharmaceutical compositions comprising antibacterial agents
AU2014338612A AU2014338612C1 (en) 2013-10-22 2014-10-22 Pharmaceutical compositions comprising antibacterial agents
PCT/IB2014/065522 WO2015059643A1 (en) 2013-10-22 2014-10-22 Pharmaceutical compositions comprising antibacterial agents
HUE14806074A HUE057504T2 (en) 2013-10-22 2014-10-22 Pharmaceutical compositions comprising antibacterial agents
KR1020167013330A KR102340010B1 (en) 2013-10-22 2014-10-22 Pharmaceutical compositions comprising antibacterial agents
MX2016005161A MX2016005161A (en) 2013-10-22 2014-10-22 Pharmaceutical compositions comprising antibacterial agents.
PT148060742T PT3060213T (en) 2013-10-22 2014-10-22 Pharmaceutical compositions comprising antibacterial agents
PL14806074T PL3060213T3 (en) 2013-10-22 2014-10-22 Pharmaceutical compositions comprising antibacterial agents
JP2019083866A JP6886996B2 (en) 2013-10-22 2019-04-25 Pharmaceutical composition containing an antibacterial agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN3309MU2013 IN2013MU03309A (en) 2013-10-22 2014-10-22

Publications (1)

Publication Number Publication Date
IN2013MU03309A true IN2013MU03309A (en) 2015-07-17

Family

ID=52003012

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3309MU2013 IN2013MU03309A (en) 2013-10-22 2014-10-22

Country Status (18)

Country Link
US (1) US9827235B2 (en)
EP (1) EP3060213B1 (en)
JP (2) JP2016538258A (en)
KR (1) KR102340010B1 (en)
CN (2) CN106102741A (en)
AU (1) AU2014338612C1 (en)
BR (1) BR112016008979B1 (en)
CA (1) CA2928364C (en)
DK (1) DK3060213T3 (en)
ES (1) ES2902456T3 (en)
HU (1) HUE057504T2 (en)
IN (1) IN2013MU03309A (en)
MX (1) MX2016005161A (en)
NZ (1) NZ719215A (en)
PL (1) PL3060213T3 (en)
PT (1) PT3060213T (en)
RU (1) RU2702361C2 (en)
WO (1) WO2015059643A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3292125B1 (en) * 2015-05-07 2019-09-04 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
MX2018014813A (en) * 2016-06-17 2019-03-14 Wockhardt Ltd Antibacterial compositions.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465428B1 (en) * 1999-08-27 2002-10-15 Aventis Pharma S.A. Pharmaceutical combinations based on dalfopristine and quinupristine, and on cefepime
JP2008524204A (en) * 2004-12-17 2008-07-10 ヴィーナス・レメディーズ・リミテッド Combination of antibiotics to give a complete solution to the treatment of infection
RU2366450C1 (en) * 2008-08-04 2009-09-10 Валентина Васильевна Малиновская Agent for severe infectious diseases and mixed infections
JP5808860B2 (en) * 2011-07-26 2015-11-10 ウォックハート リミテッド Pharmaceutical composition comprising sulbactam and beta-lactamase inhibitor
DK2748165T3 (en) * 2011-08-27 2016-12-19 Wockhardt Ltd 1,6-diazabicyclo [3,2,1] octane-7-ON DERIVATIVES AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS
US8796257B2 (en) * 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
CN105859609B (en) * 2012-05-30 2019-04-09 明治制果药业株式会社 Beta-lactamase inhibitor and preparation method thereof
CA2890894C (en) * 2013-01-14 2019-06-11 Wockhardt Limited Compositions and methods for treating bacterial infections

Also Published As

Publication number Publication date
KR102340010B1 (en) 2021-12-16
BR112016008979B1 (en) 2023-04-25
RU2016115376A (en) 2017-11-28
CA2928364C (en) 2021-11-23
PT3060213T (en) 2021-12-24
AU2014338612C1 (en) 2020-09-24
CN106102741A (en) 2016-11-09
NZ719215A (en) 2020-04-24
EP3060213A1 (en) 2016-08-31
DK3060213T3 (en) 2022-01-03
ES2902456T3 (en) 2022-03-28
JP2016538258A (en) 2016-12-08
PL3060213T3 (en) 2022-02-14
US9827235B2 (en) 2017-11-28
AU2014338612B2 (en) 2019-12-19
HUE057504T2 (en) 2022-05-28
RU2016115376A3 (en) 2018-07-02
MX2016005161A (en) 2016-10-05
JP6886996B2 (en) 2021-06-16
EP3060213B1 (en) 2021-10-13
KR20160072254A (en) 2016-06-22
BR112016008979A2 (en) 2017-08-01
CN113577084A (en) 2021-11-02
JP2019116508A (en) 2019-07-18
RU2702361C2 (en) 2019-10-08
CA2928364A1 (en) 2015-04-30
WO2015059643A1 (en) 2015-04-30
US20160303104A1 (en) 2016-10-20

Similar Documents

Publication Publication Date Title
PH12018500591A1 (en) Heterocyclic compounds and uses thereof
PH12015501996A1 (en) Heterocyclic compounds and uses thereof
TW201613911A (en) Heterocyclic compounds and uses thereof
MX2017004200A (en) Heteroaryl compounds as btk inhibitors and uses thereof.
MX2018002986A (en) Heteroaryl compounds as irak inhibitors and uses thereof.
NZ739676A (en) Heteroaryl compounds as irak inhibitors and uses thereof
IN2014MN02598A (en)
TN2015000519A1 (en) Small molecule inhibitors of fibrosis
EP3082817A4 (en) Compositions for drug administration
MX2016006815A (en) Aminopyridine derivatives as tam family kinase inhibitors.
MX2016000675A (en) Aminomethyl-biaryl derivatives as complement factor d inhibitors and uses thereof.
MX2016013431A (en) Pharmaceutical compositions comprising antibacterial agents.
MY181641A (en) Amino pyran ring derivative and composition and use thereof
MX363530B (en) Tricyclic benzoxaborole compound, preparation method therefor, and use thereof.
EP3003360A4 (en) High potency pancreatin pharmaceutical compositions
MX2018004304A (en) Quinoxaline and pyridopyrazine derivatives as pi3kbeta inhibitors.
EP3244930A4 (en) Pharmaceutical compositions comprising poh derivatives
IN2013MU03309A (en)
IN2013MU03704A (en)
IN2013MU03422A (en)
IN2013MU03308A (en)
IN2013MU03421A (en)
IN2014MU00859A (en)
IN2013MU03565A (en)
MX2017010992A (en) Stable pharmaceutical compositions comprising antibacterial agent.